Sudeep Pharma cash flow

Latest FY26
Cash from operations
₹69.6cr 
Capital spending
₹118cr 
Free cash flow
−₹48.6cr 
Cash from financing
₹247cr 
₹ crore except per share
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026
Adjustments to reconcile profit — non-cash items
—14.8
—7.6
—−3.4
—−0.1
—−15.0
Changes in working capital
—−79.9
—−16.4
—4.5
—−0.4
—−12.1
—−0.1
—−2.0
—1.2
—0.3
—−1.7
Cash from operating activities
250228
—−103
—126
—−0.5
—55.5
—69.6
Cash from investing activities
—118
—87.8
—0.3
—125
—3.4
—−327
Cash from financing activities
—95.0
—160
—21.6
—10.3
—0.9
—11.3
—−6.7
—247
—−10.3
—0.3
—−10.1
Reference items
251222
35.3%34.6%
−48.6−48.6
−₹4.30−₹4.30
—0.40×
—55.5
—11.3
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SUDEEPPHRM₹1,130.10

Sudeep Pharma Ltd.

· Chemicals
₹ CrorePeersSUDARSCHEMSTYRENIXSHARDACROPREFEXRCFRALLISRAINPRIVISCLMcap ₹12,764 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY26
31/03/2026
Last 12M
30/09/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation14.8—
+ Finance Costs7.6—
+ Interest Income-3.4—
+ Fair Value (Gains) / Losses-0.1—
+ Unrealised FX (Gain) / Loss-15.0—
Changes in Working Capital
+ Inventories-79.9—
+ Trade Receivables — Current-16.4—
+ Other Financial Assets — Current4.5—
+ Other Financial Assets — Non-current-0.4—
+ Other Current Assets-12.1—
+ Other Non-current Assets-0.1—
+ Trade Payables — Current-2.0—
+ Other Financial Liabilities — Current1.2—
+ Provisions — Current0.3—
+ Provisions — Non-current-1.7—
Cash from Operating Activities
Profit Before Tax (per I/S)228.1249.8
+ Total Adjustments (incl. Working Capital)-102.6—
Cash from Operations (pre-tax)125.5—
+ Other Inflows / (Outflows) — Operating-0.5—
+ Income Taxes Paid55.5—
Cash from Operating Activities69.6—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)118.1—
+ Acq of Investment Property87.8—
+ Disp of Investment Property0.3—
+ Acq of Subsidiaries / Businesses (net)124.8—
+ Interest Received — Investing3.4—
Cash from Investing Activities-327.2—
Cash from Financing Activities
+ Proceeds from Issue of Shares95.0—
+ Proceeds from Other Equity Instruments160.0—
+ Proceeds from Borrowings21.6—
+ Repayment of Borrowings10.3—
+ Payment of Lease Liabilities0.9—
+ Interest Paid11.3—
+ Other Inflows / (Outflows) — Financing-6.7—
Cash from Financing Activities247.3—
Net Changes in Cash (pre-FX)-10.3—
+ Effect of FX Rate Changes on Cash0.3—
Net Changes in Cash-10.1—
Reference Items
EBITDA221.9250.7
EBITDA Margin %34.5535.33
Free Cash Flow (CFO − Capex)-48.6-48.6
Free Cash Flow per Basic Share-4.30-4.30
Cash Flow to Net Income0.40—
Cash Paid for Taxes55.5—
Cash Paid for Interest11.3—
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.